Liminatus Pharma Inc (LIMN) is not a good buy for a beginner, long-term investor at this time. The stock demonstrates weak technical indicators, no positive trading trends, and lacks significant catalysts or growth in financial performance. Additionally, there are no proprietary trading signals suggesting a strong buy opportunity.

Technical Analysis

The stock shows bearish technical indicators with MACD below 0 (-0.067) and negatively contracting, RSI at 26.631 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 0.21, and resistance is at 0.561, indicating limited upward momentum.

Positive Catalysts

NULL identified. No recent news, trading trends, or significant financial improvements.

Neutral/Negative Catalysts

The stock's regular market change is -3.77%, and financial performance shows no revenue growth. Insider and hedge fund activity are neutral, and technical indicators are bearish.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -1,823,351 (up 202.98% YoY), and an EPS of -0.07 (up 250% YoY). Gross margin remains at 0, showing no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast LIMN stock price to rise

Buy

Hold

Sell

Current: 0.253

Low

Averages

High